Remove Bioinformatics Remove RNA Remove Therapies
article thumbnail

Brusatol induces ferroptosis to inhibit hepatocellular carcinoma progression by targeting ATF3

Chemical Biology and Drug Design

Using RNA-seq and through in vitro and in vivo studies, we determined that brusatol suppresses hepatocellular carcinoma progression by inducing ATF3-mediated ferroptosis. Therefore, our research revealed the biological effect of brusatol treatment and provided ATF3 as a novel therapeutic target and prognostic biomarker for HCC therapy.

RNA 100
article thumbnail

Identification of a 2?phenylthiazole derivative acetylcholinesterase modulator with in vitro antitumor activity in breast cancer cells

Chemical Biology and Drug Design

To clarify how A6 affected on MCF-7 cells, RNA-seq analysis was conducted to evaluate the whole genome effect of A6 on gene expression. Moreover, bioinformatic analysis and cell viability test showed A6 plays anticancer role by regulating Best1 and HIST1H2BJ. In addition, A6 induced apoptosis of MCF-7 cells.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Key industry partnerships advancing drug discovery

Drug Discovery World

Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis’ hereditary angioedema (HAE) drug candidate donidalorsen in Europe.

article thumbnail

Leveraging ADCs in precision oncology strategy

Drug Target Review

What role do ADCs play in Caris’ strategy for targeted cancer therapy, particularly in terms of patient-specific treatment plans? Patient specific treatment plans can be tailored to the cohorts that express the targets including feasibility assessment of combinations of our ADC targets with other lines of therapy.

article thumbnail

Looking ahead to AACR  

Drug Discovery World

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

article thumbnail

How big data analytics can make personalised care a reality

Drug Discovery World

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. Figure 2: Advanced data visualisation examples for transcriptomics data.

article thumbnail

The microbiome in precision medicine

Drug Discovery World

This leap in understanding, which has been facilitated by the emergence of next generation sequencing (NGS) technologies and bioinformatics tools such as artificial intelligence (AI), has brought forward a new wave of precision medicine resources, diagnostics, and therapeutics specifically aiming to leverage the microbiome.